🔴 Absci is trading 10.1% down with no verified company-specific catalyst identified

Absci is trading 10.1% down at $10.37 on October 6, 2026, with no verified company-specific announcement identified to explain the decline.

• Biotech shares were under broad pressure; the XBI was down 2.94% in MarketWatch’s October 6 midday quote.
• Absci’s latest identified company update was September 24, about planned Phase 2 STORYLINE trial details. Sector weakness offers context but does not fully explain the decline; available reporting does not establish a specific catalyst or direct cause.